These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 10080605

  • 1. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L.
    J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
    [Abstract] [Full Text] [Related]

  • 2. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.
    Garland J, Buscombe JR, Bouvier C, Bouloux P, Chapman MH, Chow AC, Reynolds N, Caplin ME.
    Aliment Pharmacol Ther; 2003 Feb; 17(3):437-44. PubMed ID: 12562458
    [Abstract] [Full Text] [Related]

  • 3. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
    Rosenoff S.
    Support Care Cancer; 2004 Aug; 12(8):561-70. PubMed ID: 15160318
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
    Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC.
    Ann Oncol; 2017 Jul 01; 28(7):1569-1575. PubMed ID: 28444114
    [Abstract] [Full Text] [Related]

  • 5. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA, Wolin EM, Liyanage N, Lowenthal SP, Mirakhur B, Pommier RF, Shaheen M, Vinik AI, ELECT Study Investigators.
    Endocr Pract; 2018 Mar 01; 24(3):243-255. PubMed ID: 29547049
    [Abstract] [Full Text] [Related]

  • 6. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE, Thornton-Jones VA, Wass JA.
    Clin Endocrinol (Oxf); 2004 Aug 01; 61(2):224-31. PubMed ID: 15272918
    [Abstract] [Full Text] [Related]

  • 7. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA.
    Bull Acad Natl Med; 1989 May 01; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [Abstract] [Full Text] [Related]

  • 8. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
    Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB.
    J Med Econ; 2017 Sep 01; 20(9):945-951. PubMed ID: 28562131
    [Abstract] [Full Text] [Related]

  • 9. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
    Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC, RADIANT-2 Study Group.
    Lancet; 2011 Dec 10; 378(9808):2005-2012. PubMed ID: 22119496
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K.
    Drug Des Devel Ther; 2015 Dec 10; 9():5075-86. PubMed ID: 26366058
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG.
    N Engl J Med; 1986 Sep 11; 315(11):663-6. PubMed ID: 2427948
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
    Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.
    Oncologist; 2014 Sep 11; 19(9):930-6. PubMed ID: 25096997
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
    Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, Ducreux M, Lombard-Bohas C, de Herder WW, Delle Fave G, Reed N, Seitz JF, Van Cutsem E, Grossman A, Rougier P, Schmidt W, Wiedenmann B.
    Neuroendocrinology; 2004 Sep 11; 80(4):244-51. PubMed ID: 15627802
    [Abstract] [Full Text] [Related]

  • 20. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
    Oberg K, Norheim I, Theodorsson E, Ahlman H, Lundqvist G, Wide L.
    J Clin Endocrinol Metab; 1989 Apr 11; 68(4):796-800. PubMed ID: 2466045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.